Literature DB >> 12149113

Dynamic computed tomography with low- and high-molecular-mass contrast agents to assess microvascular permeability modifications in a model of liver fibrosis.

Roland Materne1, Laurence Annet, Stéphane Dechambre, Christine Sempoux, Anne M Smith, Claire Corot, Yves Horsmans, Bernard E Van Beers.   

Abstract

Interstitial collagen formation and transformation of the fenestrated hepatic sinusoids into continuous capillaries are major ultrastructural changes that occur in liver cirrhosis and fibrosis. These modifications lead to progressive restriction of blood-liver exchanges. The purpose of our study was to evaluate the permeability changes in a model of hepatic fibrosis by using dynamic computed tomography (CT) enhanced with contrast agents of different molecular masses. Dynamic single-section CT of the liver was performed after intravenous bolus administration of a low-molecular-mass contrast agent (iobitridol) and an experimental high-molecular-mass agent (P840) in normal control rabbits and in rabbits with hepatic fibrosis. Hepatic, aortic and portal venous time-density curves were fitted with a dual-input one-compartmental model to calculate the hepatic mean transit time and distribution volume of the contrast agents. In the rabbits with liver fibrosis, the mean transit time of the high-molecular-mass agent was shorter than that of the low-molecular-mass agent (10.0+/-1.8 s and 12.0+/-1.2 s respectively; P<0.05). The distribution volume accessible to the high-molecular-mass agent was also smaller (22.2+/-4.8% compared with 32.0+/-6.7%; P<0.01). In the normal rabbits, the mean transit times of the high- and low-molecular-mass agents did not differ significantly, and nor did their distribution volumes. Our results demonstrate decreased sinusoidal permeability for the high-molecular-mass agent P840 in a model of hepatic fibrosis. Non-invasive assessment of permeability changes in liver fibrosis can be performed with dynamic CT and contrast agents of different molecular masses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149113     DOI: 10.1042/cs1030213

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

Review 1.  The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.

Authors:  David G Le Couteur; Robin Fraser; Sarah Hilmer; Laurent P Rivory; Allan J McLean
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling.

Authors:  Tong San Koh; Choon Hua Thng; Septian Hartono; Puor Sherng Lee; Su Pin Choo; Donald Y H Poon; Han Chong Toh; Sotirios Bisdas
Journal:  Eur Radiol       Date:  2009-01-10       Impact factor: 5.315

Review 3.  Perfusion magnetic resonance imaging of the liver.

Authors:  Choon Hua Thng; Tong San Koh; David J Collins; Dow Mu Koh
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

4.  Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent.

Authors:  Laure S Fournier; Charles Andre Cuenod; Cedric de Bazelaire; Nathalie Siauve; Christophe Rosty; Phuong Lan Tran; Guy Frija; Olivier Clement
Journal:  Eur Radiol       Date:  2004-07-29       Impact factor: 5.315

Review 5.  A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

Authors:  Waqar Ahmad; Bushra Ijaz; Sana Gull; Sultan Asad; Saba Khaliq; Shah Jahan; Muhammad T Sarwar; Humera Kausar; Aleena Sumrin; Imran Shahid; Sajida Hassan
Journal:  Virol J       Date:  2011-02-08       Impact factor: 4.099

6.  Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors.

Authors:  Ya-Wen Chen; Huay-Ben Pan; Hui-Hwa Tseng; Yu-Ting Hung; Jer-Shyung Huang; Chen-Pin Chou
Journal:  Int J Mol Sci       Date:  2013-08-27       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.